.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC01_Cytarabine.Cytarabine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC01_Cytarabine.Cytarabine| name: | Cytarabine |
| ATC code: | L01BC01 | route: | intravenous |
| n-compartments | 2 |
Cytarabine (also known as Ara-C) is a cytosine nucleoside analog used primarily as an antimetabolite chemotherapy agent for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), and non-Hodgkin's lymphoma. It inhibits DNA synthesis in rapidly dividing cells. Cytarabine is an approved and widely used chemotherapy drug.
Pharmacokinetic parameters from adults with acute myeloid leukemia treated via intravenous infusion; values reflect population pharmacokinetics.
Mancini, SL, et al., & Messenger, KM (2022). Novel subcutaneous cytarabine infusion with the Omnipod system in dogs with meningoencephalomyelitis of unknown etiology. American journal of veterinary research 83(9) –. DOI:10.2460/ajvr.22.03.0046 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35895763
Feldman, EJ, et al., & Plezia, P (1993). Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 11(10) 2002–2009. DOI:10.1200/JCO.1993.11.10.2002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8410125
Periclou, AP, & Avramis, VI (1996). NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer chemotherapy and pharmacology 39(1-2) 42–50. DOI:10.1007/s002800050536 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8995498